Pentiapine (CGS 10746) is a novel inhibitor of dopamine release.

Pentiapine effectively reduces motor activity in mice, both independently and in diminishing morphine-induced hyperactivity, on a dose-dependent basis. Analysis through Newman-Keuls post-hoc comparisons reveals that mice administered morphine and saline exhibit higher activity levels compared to those treated with incremental doses of 2 to 32 mg/kg of Pentiapine, with significant activity reductions observed at the 2 (P<0.05) and 32 (P<0.01) mg/kg levels. Additionally, lower doses of Pentiapine (0.5, 1, and 2 mg/kg) result in more activity than higher doses (4 to 32 mg/kg) in morphine-treated groups (P<0.01)[1]. A 30 mg/kg dose of Pentiapine completely inhibits the conditioned place preference (CPP) induced by methylenedioxymethamphetamine (MDMA) and prevents the establishment of a cocaine-induced CPP[2], demonstrating its potential in mitigating addictive behaviors.

DMSO: 100 mg/mL (334.01 mM), Sonication is recommended.